Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach ; day:30 ; month:4 ; year:2024 ; pages:1-5
Leukemia ; (30.4.2024), 1-5
- Creator
-
Walker, Ieuan G.
Roy, James P.
Anderson, Georgina S. F.
Guerrero Lopez, Jose
Chapman, Michael A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-024-02247-1
- URN
-
urn:nbn:de:101:1-2407122131564.978237047620
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Walker, Ieuan G.
- Roy, James P.
- Anderson, Georgina S. F.
- Guerrero Lopez, Jose
- Chapman, Michael A.
- SpringerLink (Online service)
Other Objects (12)
Pharmacological control of CAR T-cells by dasatinib
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Prospects for combined use of oncolytic viruses and CAR T-cells
CAR-T cells in multiple myeloma: current status
CAR T-cells for pediatric solid tumors: where to go from here?
The essential effector role of T-cells in bacteria-mediated tumor therapy
CAR T therapies in multiple myeloma: unleashing the future
Updates on CAR T cell therapy in multiple myeloma
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Pharmacological control of CAR T-cells by dasatinib
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Prospects for combined use of oncolytic viruses and CAR T-cells
CAR-T cells in multiple myeloma: current status
CAR T-cells for pediatric solid tumors: where to go from here?
The essential effector role of T-cells in bacteria-mediated tumor therapy
CAR T therapies in multiple myeloma: unleashing the future
Updates on CAR T cell therapy in multiple myeloma
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression
Pharmacological control of CAR T-cells by dasatinib
Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
Digital-droplet PCR for quantification of CD19-directed CAR T-cells
Prospects for combined use of oncolytic viruses and CAR T-cells
CAR-T cells in multiple myeloma: current status
CAR T-cells for pediatric solid tumors: where to go from here?
The essential effector role of T-cells in bacteria-mediated tumor therapy
CAR T therapies in multiple myeloma: unleashing the future
Updates on CAR T cell therapy in multiple myeloma
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics